The last week before the May Day holiday did not see any new stocks listed. However, based on previous trends, if one can get a subscription, making a good profit from new shares is still highly probable.
In the first week after May Day (from May 6 to 9), three new stocks will be open for subscription. After the short holiday for new share subscriptions, it will be busy again.
<h2>Three Companies Queueing for Listing</h2>
Among them, there are two pharmaceutical stocks, both focusing on the field of medical device consumables that have primarily relied on imports in the past.
Hanbon Technology focuses on chromatography technology, mainly providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors.
According to data from Sullivan, in 2023, it ranked second in the liquid chromatography equipment market with a market share of approximately 12.7%, leading among domestic brands.
Weigao Blood has focused on the research, development, production, and sales of blood purification medical products since its establishment.
According to Sullivan data, in the segmented market of blood dialysis consumables, the company held a market share of 32.5% in the domestic blood dialysis machine field in 2023, ranking first in the industry; in the domestic blood dialysis tubing field, its market share was 31.8%, also ranking first in the industry.
In addition to the two medical device companies mentioned above, there is also Taili Technology, which will be listed on the Growth Enterprise Market on May 8 (Wednesday).
This company focuses on the research and development of new materials and the industrial application of vacuum technology.
<h2>Individual Companies Have Patent Disputes</h2>
Hanbon Technology has a considerable professional threshold in the field of chromatography technology. In 2023, the market size of production-level small molecule liquid chromatography systems in China was approximately 780 million yuan, with Hanbon Technology holding a market share of 39.2%, ranking first.
Over the past three years, the company's revenue was approximately 482 million yuan, 619 million yuan, and 691 million yuan, with year-on-year growth rates of 50.32%, 28.48%, and 11.61%; net profits were approximately 38.56 million yuan, 51.50 million yuan, and 79.34 million yuan, with year-on-year growth rates of 693.13%, 33.44%, and 54.06%.
Revenue growth is stable, gross profit margins have continued to rise over three years, and net profit growth is also expected to increase in 2024, indicating stable and positive performance.
However, Hanbon Technology is facing patent disputes regarding its core patents, with international giant Sitaofan filing lawsuits against Hanbon Technology over three patents.
One case has been dismissed and is still in the appeal stage, one &#34;chromatography column&#34; patent has been deemed infringing, but the National Intellectual Property Administration has announced that all &#34;chromatography column&#34; patents are invalid, and one case has not yet been heard.
Moreover, its R&amp;D expense ratio has been in a relatively low position compared to comparable peers for three consecutive years, which poses a challenge for the future.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/a8a0e04a-65f7-4a00-8cef-4202e9fd1016.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/a8a0e04a-65f7-4a00-8cef-4202e9fd1016.png"/>
<h2>Transitioning to A-share Medical Enterprises</h2>
Another company, Weigao Blood, previously attempted to list on the Hong Kong Stock Exchange in June 2022 but was unsuccessful. This time, it is shifting its focus to the A-share market and is receiving significant attention.
Since its establishment, Weigao Blood has focused on the research, development, production, and sales of medical products for blood purification.
According to data from Sullivan, in the blood dialysis consumables segment, the company held a market share of 32.5% in the domestic blood dialysis machine field in 2023, ranking first in the industry; in the domestic blood dialysis tubing field, its market share was 31.8%, also ranking first in the industry.
The company's operating performance is relatively stable, but the growth rate of revenue and net profit has stabilized in recent years, showing no high growth. Over the past three years, the company's revenue was approximately 3.426 billion yuan, 3.532 billion yuan, and 3.604 billion yuan, respectively; the net profit attributable to the parent company was approximately 315 million yuan, 442 million yuan, and 449 million yuan, respectively.
Similar to Hanbon, Weigao Blood's R&amp;D investment ratio is also relatively low, with R&amp;D expense ratios around 4%-5% over the past three years, which is not high.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/8a973036-7d46-4f40-a143-fa259ef85b0c.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/8a973036-7d46-4f40-a143-fa259ef85b0c.png"/>
<h2>Compression Bag Supplier &#34;Ai&#34; Online</h2>
In addition to the two medical device companies mentioned above, another company, Taili Technology, will be listed on the ChiNext board on May 8 (Wednesday).
This company focuses on the research and development of new materials and the industrial application of vacuum technology.
It is worth mentioning that in the development of vacuum storage products, the company is the exclusive supplier of compression bags for China's aerospace sector, and related products have also entered fields such as the military, banks, and hospitals.
Currently, from 2021 to 2023, the company's market share on the Tmall platform was 27.98%, 22.24%, and 22.13%, respectively, ranking first in the market.
The company is also the sole supplier of vacuum suction cup products for retail giants such as IKEA and Walmart.
Over the past three years, the company's revenue was approximately 638 million yuan, 835 million yuan, and 1.02 billion yuan, with year-on-year growth rates of 2.38%, 30.95%, and 22.07%, respectively; the net profit attributable to the parent company was approximately 58.83 million yuan, 84.96 million yuan, and 87.64 million yuan, with year-on-year growth rates of 34.99%, 44.40%, and 3.16%.
The prospectus states that due to the high proportion of online sales, which is around 80%, and the increasingly fierce competition in promotional marketing among e-commerce platform merchants, the company's promotional costs are on the rise. This will have a certain impact on net profit.
Risk Warning and Disclaimer
The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not consider the specific investment goals, financial conditions, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investing based on this is at their own risk

603014

688755

After the May Day holiday, three new stocks opened for subscription, two of which are pharmaceutical stocks: Hanbon and Weigao Blood. Hanbon holds a market share of 12.7% in the liquid chromatography equipment market, while Weigao Blood has a market share of 32.5% and 31.8% in the blood dialysis market, respectively. In addition, Taili Technology will also be listed on May 8. Hanbon is facing patent disputes, but its revenue and net profit continue to grow, showing a stable and positive performance trend

Wallstreetcn

Post-holiday IPOs "double-edged sword": Potential companies face "great challenges," leading enterprises have "many controversies."